Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats
BackgroundCombination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY3-36) have not been directly compared t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-01-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2020.598843/full |
| _version_ | 1818612662992371712 |
|---|---|
| author | Ulrich Dischinger Julia Hasinger Malina Königsrainer Carolin Corteville Christoph Otto Martin Fassnacht Mohamed Hankir Florian Johannes David Seyfried |
| author_facet | Ulrich Dischinger Julia Hasinger Malina Königsrainer Carolin Corteville Christoph Otto Martin Fassnacht Mohamed Hankir Florian Johannes David Seyfried |
| author_sort | Ulrich Dischinger |
| collection | DOAJ |
| description | BackgroundCombination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY3-36) have not been directly compared to Roux-en-Y gastric bypass (RYGB) in a standardized experimental setting.MethodsHigh-fat diet (HFD)-induced obese male Wistar rats were randomized into six treatment groups: (1) RYGB, (2) sham-operation (shams), (3) liraglutide, (4) PYY3-36, (5) PYY3-36+liraglutide (6), saline. Animals were kept on a free choice high- and low-fat diet. Food intake, preference, and body weight were measured daily for 4 weeks. Open field (OP) and elevated plus maze (EPM) tests were performed.ResultsRYGB reduced food intake and achieved sustained weight loss. Combined PYY3-36+liraglutide treatment led to similar and plateaued weight loss compared to RYGB. Combined PYY3-36+liraglutide treatment was superior to PYY3-36 (p ≤ 0.0001) and liraglutide (p ≤ 0.05 or p ≤ 0.01) mono-therapy. PYY3-36+liraglutide treatment and RYGB also reduced overall food intake and (less pronounced) high-fat preference compared to controls. The animals showed no signs of abnormal behavior in OF or EPM.ConclusionsLiraglutide and PYY3-36 combination therapy vastly mimics reduced food intake, food choice and weight reducing benefits of RYGB. |
| first_indexed | 2024-12-16T15:49:48Z |
| format | Article |
| id | doaj.art-f3ee28bfcd634d13a7ef5ec7066f8ee3 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-16T15:49:48Z |
| publishDate | 2021-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-f3ee28bfcd634d13a7ef5ec7066f8ee32022-12-21T22:25:44ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-01-011110.3389/fendo.2020.598843598843Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese RatsUlrich Dischinger0Julia Hasinger1Malina Königsrainer2Carolin Corteville3Christoph Otto4Martin Fassnacht5Mohamed Hankir6Florian Johannes David Seyfried7Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, GermanyDepartment of General, Visceral, Transplant, Vascular and Pediatric Surgery, University Hospital, University of Würzburg, Würzburg, GermanyBackgroundCombination therapies of anorectic gut hormones partially mimic the beneficial effects of bariatric surgery. Thus far, the effects of a combined chronic systemic administration of Glucagon-like peptide-1 (GLP-1) and peptide tyrosine tyrosine 3-36 (PYY3-36) have not been directly compared to Roux-en-Y gastric bypass (RYGB) in a standardized experimental setting.MethodsHigh-fat diet (HFD)-induced obese male Wistar rats were randomized into six treatment groups: (1) RYGB, (2) sham-operation (shams), (3) liraglutide, (4) PYY3-36, (5) PYY3-36+liraglutide (6), saline. Animals were kept on a free choice high- and low-fat diet. Food intake, preference, and body weight were measured daily for 4 weeks. Open field (OP) and elevated plus maze (EPM) tests were performed.ResultsRYGB reduced food intake and achieved sustained weight loss. Combined PYY3-36+liraglutide treatment led to similar and plateaued weight loss compared to RYGB. Combined PYY3-36+liraglutide treatment was superior to PYY3-36 (p ≤ 0.0001) and liraglutide (p ≤ 0.05 or p ≤ 0.01) mono-therapy. PYY3-36+liraglutide treatment and RYGB also reduced overall food intake and (less pronounced) high-fat preference compared to controls. The animals showed no signs of abnormal behavior in OF or EPM.ConclusionsLiraglutide and PYY3-36 combination therapy vastly mimics reduced food intake, food choice and weight reducing benefits of RYGB.https://www.frontiersin.org/articles/10.3389/fendo.2020.598843/fullobesityrygbliraglutidepeptide tyrosine tyrosine (PYY)treatmentgastric bypass |
| spellingShingle | Ulrich Dischinger Julia Hasinger Malina Königsrainer Carolin Corteville Christoph Otto Martin Fassnacht Mohamed Hankir Florian Johannes David Seyfried Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats Frontiers in Endocrinology obesity rygb liraglutide peptide tyrosine tyrosine (PYY) treatment gastric bypass |
| title | Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats |
| title_full | Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats |
| title_fullStr | Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats |
| title_full_unstemmed | Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats |
| title_short | Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY3-36 Combination Therapy in Diet-Induced Obese Rats |
| title_sort | toward a medical gastric bypass chronic feeding studies with liraglutide pyy3 36 combination therapy in diet induced obese rats |
| topic | obesity rygb liraglutide peptide tyrosine tyrosine (PYY) treatment gastric bypass |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2020.598843/full |
| work_keys_str_mv | AT ulrichdischinger towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT juliahasinger towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT malinakonigsrainer towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT carolincorteville towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT christophotto towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT martinfassnacht towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT mohamedhankir towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats AT florianjohannesdavidseyfried towardamedicalgastricbypasschronicfeedingstudieswithliraglutidepyy336combinationtherapyindietinducedobeserats |